Insider Selling: Abrdn Life Sciences Investors (NYSE:HQL) Major Shareholder Sells $16,651.54 in Stock

Posted by Sarita Garza on May 11th, 2025

Abrdn Life Sciences Investors (NYSE:HQL – Get Free Report) major shareholder Saba Capital Management, L.P. sold 1,366 shares of the company’s stock in a transaction that occurred on Wednesday, May 7th. The stock was sold at an average price of $12.19, for a total value of $16,651.54. Following the sale, the insider now directly owns 3,066,706 shares of the company’s stock, valued at $37,383,146.14. The trade was a 0.04 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Saba Capital Management, L.P. also recently made the following trade(s):

On Thursday, April 17th, Saba Capital Management, L.P. sold 9,144 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $11.78, for a total transaction of $107,716.32.
On Monday, April 14th, Saba Capital Management, L.P. sold 15,400 shares of Abrdn Life Sciences Investors stock. The shares were sold at an average price of $11.67, for a total transaction of $179,718.00.
On Thursday, April 10th, Saba Capital Management, L.P. sold 30,156 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $11.14, for a total transaction of $335,937.84.
On Friday, April 4th, Saba Capital Management, L.P. sold 6,889 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $11.57, for a total transaction of $79,705.73.
On Wednesday, April 2nd, Saba Capital Management, L.P. sold 29,102 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $12.28, for a total value of $357,372.56.
On Monday, March 31st, Saba Capital Management, L.P. sold 48,623 shares of Abrdn Life Sciences Investors stock. The shares were sold at an average price of $12.58, for a total transaction of $611,677.34.
On Thursday, March 27th, Saba Capital Management, L.P. sold 32,922 shares of Abrdn Life Sciences Investors stock. The shares were sold at an average price of $13.01, for a total transaction of $428,315.22.
On Wednesday, February 26th, Saba Capital Management, L.P. sold 200 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $13.62, for a total value of $2,724.00.
On Wednesday, February 12th, Saba Capital Management, L.P. sold 36,536 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $13.75, for a total value of $502,370.00.
On Monday, February 10th, Saba Capital Management, L.P. sold 42,987 shares of Abrdn Life Sciences Investors stock. The shares were sold at an average price of $13.95, for a total value of $599,668.65.

Abrdn Life Sciences Investors Stock Performance

Shares of HQL opened at $11.98 on Friday. Abrdn Life Sciences Investors has a one year low of $10.55 and a one year high of $15.90. The firm has a 50 day simple moving average of $12.39 and a two-hundred day simple moving average of $13.43.

Abrdn Life Sciences Investors Cuts Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, March 31st. Investors of record on Friday, February 21st were given a dividend of $0.47 per share. The ex-dividend date was Friday, February 21st. This represents a $1.88 dividend on an annualized basis and a yield of 15.69%.

Hedge Funds Weigh In On Abrdn Life Sciences Investors

Several institutional investors and hedge funds have recently added to or reduced their stakes in HQL. BankPlus Trust Department bought a new position in shares of Abrdn Life Sciences Investors in the 4th quarter worth about $28,000. Steward Partners Investment Advisory LLC raised its stake in shares of Abrdn Life Sciences Investors by 379.8% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 4,860 shares of the company’s stock worth $64,000 after purchasing an additional 3,847 shares during the period. Wealthcare Advisory Partners LLC bought a new position in Abrdn Life Sciences Investors during the first quarter valued at $131,000. Cambridge Investment Research Advisors Inc. purchased a new position in shares of Abrdn Life Sciences Investors in the first quarter worth about $134,000. Finally, Wedbush Securities Inc. bought a new stake in shares of Abrdn Life Sciences Investors during the 1st quarter valued at $149,000. 32.21% of the stock is currently owned by institutional investors and hedge funds.

Abrdn Life Sciences Investors Company Profile

(Get Free Report)

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.